With CastleVax, the health system said it plans to evaluate its vaccine platform technology developed from Newcastle disease virus, which birds can contract but is harmless to people. The company is currently testing a potential COVID-19 nasal vaccine in an early trial and will embark on an omicron-targeted vaccine candidate, which other vaccine-makers are racing to distribute this fall.
“COVID-19 is the first step for our platform development,” Matt Stober, CastleVax president and CEO, said in a statement. “We aim to engineer vaccines to fight a broad range of future respiratory pandemic threats that experts in the field foresee as inevitable.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.